The pharmacokinetics of antimicrobials in patients with obesity remains largely unknown, though it is likely that they diverge significantly from those of the non-obese. This would make the current dosing regimens for obese critically ill patients highly sub-optimal.

This multi-centre study will describe the pharmacokinetics of piperacillin, meropenem and fluconazole in critically ill obese patients.